137 related articles for article (PubMed ID: 34642184)
1. Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors.
Hawley JR; Zhou S; Arlidge C; Grillo G; Kron KJ; Hugh-White R; van der Kwast TH; Fraser M; Boutros PC; Bristow RG; Lupien M
Cancer Res; 2021 Dec; 81(23):5833-5848. PubMed ID: 34642184
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation-based chromatin compartments and ChIP-seq profiles reveal transcriptional drivers of prostate carcinogenesis.
Simmonds P; Loomis E; Curry E
Genome Med; 2017 Jun; 9(1):54. PubMed ID: 28592290
[TBL] [Abstract][Full Text] [Related]
3. Discovery of regulatory noncoding variants in individual cancer genomes by using cis-X.
Liu Y; Li C; Shen S; Chen X; Szlachta K; Edmonson MN; Shao Y; Ma X; Hyle J; Wright S; Ju B; Rusch MC; Liu Y; Li B; Macias M; Tian L; Easton J; Qian M; Yang JJ; Hu S; Look AT; Zhang J
Nat Genet; 2020 Aug; 52(8):811-818. PubMed ID: 32632335
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'?
Walsh AL; Tuzova AV; Bolton EM; Lynch TH; Perry AS
Trends Mol Med; 2014 Aug; 20(8):428-36. PubMed ID: 24836411
[TBL] [Abstract][Full Text] [Related]
5. A Deep Learning Framework Identifies Pathogenic Noncoding Somatic Mutations from Personal Prostate Cancer Genomes.
Wang C; Li J
Cancer Res; 2020 Nov; 80(21):4644-4654. PubMed ID: 32907840
[TBL] [Abstract][Full Text] [Related]
6. The New Frontier of Functional Genomics: From Chromatin Architecture and Noncoding RNAs to Therapeutic Targets.
Papanicolaou N; Bonetti A
SLAS Discov; 2020 Jul; 25(6):568-580. PubMed ID: 32486876
[TBL] [Abstract][Full Text] [Related]
7. Noncoding RNA for personalized prostate cancer treatment: utilizing the 'dark matters' of the genome.
Hua J; Lu J; Isaev K; Soares F; Guo H; Ahmed M; He HH
Per Med; 2017 Mar; 14(2):159-169. PubMed ID: 29754555
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel oncogenic events occurring early in prostate carcinogenesis using purified autologous malignant and non-malignant prostate epithelial cells.
Sluka P; Pezaro C; Wardan H; Sengupta S; Davis ID
BJU Int; 2019 May; 123 Suppl 5():27-35. PubMed ID: 30712320
[TBL] [Abstract][Full Text] [Related]
9. Punctuated evolution of prostate cancer genomes.
Baca SC; Prandi D; Lawrence MS; Mosquera JM; Romanel A; Drier Y; Park K; Kitabayashi N; MacDonald TY; Ghandi M; Van Allen E; Kryukov GV; Sboner A; Theurillat JP; Soong TD; Nickerson E; Auclair D; Tewari A; Beltran H; Onofrio RC; Boysen G; Guiducci C; Barbieri CE; Cibulskis K; Sivachenko A; Carter SL; Saksena G; Voet D; Ramos AH; Winckler W; Cipicchio M; Ardlie K; Kantoff PW; Berger MF; Gabriel SB; Golub TR; Meyerson M; Lander ES; Elemento O; Getz G; Demichelis F; Rubin MA; Garraway LA
Cell; 2013 Apr; 153(3):666-77. PubMed ID: 23622249
[TBL] [Abstract][Full Text] [Related]
10. Novel RNA markers in prostate cancer: functional considerations and clinical translation.
Pickl JM; Heckmann D; Ratz L; Klauck SM; Sültmann H
Biomed Res Int; 2014; 2014():765207. PubMed ID: 25250334
[TBL] [Abstract][Full Text] [Related]
11. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
12. eRNAs and Superenhancer lncRNAs Are Functional in Human Prostate Cancer.
Zhang X; Pang P; Jiang M; Cao Q; Li H; Xu Y; Li Y; Chen X; Han J
Dis Markers; 2020; 2020():8847986. PubMed ID: 33029258
[TBL] [Abstract][Full Text] [Related]
13. Histone modifications and chromatin organization in prostate cancer.
Chen Z; Wang L; Wang Q; Li W
Epigenomics; 2010 Aug; 2(4):551-60. PubMed ID: 21318127
[TBL] [Abstract][Full Text] [Related]
14. The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression.
Qian Y; Zhang L; Cai M; Li H; Xu H; Yang H; Zhao Z; Rhie SK; Farnham PJ; Shi J; Lu W
Sci Adv; 2019 Jul; 5(7):eaaw6710. PubMed ID: 31328168
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.
Dhingra P; Martinez-Fundichely A; Berger A; Huang FW; Forbes AN; Liu EM; Liu D; Sboner A; Tamayo P; Rickman DS; Rubin MA; Khurana E
Genome Biol; 2017 Jul; 18(1):141. PubMed ID: 28750683
[TBL] [Abstract][Full Text] [Related]
16. Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations.
Zhou S; Treloar AE; Lupien M
Cancer Discov; 2016 Nov; 6(11):1215-1229. PubMed ID: 27807102
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic insights into genetic susceptibility to prostate cancer.
Tian P; Zhong M; Wei GH
Cancer Lett; 2021 Dec; 522():155-163. PubMed ID: 34560228
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic Properties of NEAT1 in Prostate Cancer Cells Depend on the CDC5L-AGRN Transcriptional Regulation Circuit.
Li X; Wang X; Song W; Xu H; Huang R; Wang Y; Zhao W; Xiao Z; Yang X
Cancer Res; 2018 Aug; 78(15):4138-4149. PubMed ID: 29871935
[TBL] [Abstract][Full Text] [Related]
19. Modeling human prostate cancer progression in vitro.
Liu TT; Ewald JA; Ricke EA; Bell R; Collins C; Ricke WA
Carcinogenesis; 2019 Jul; 40(7):893-902. PubMed ID: 30590461
[TBL] [Abstract][Full Text] [Related]
20. Methods to Study RNA-Chromatin Interactions.
Sriram K; Luo Y; Malhi NK; Chen AT; Chen ZB
Methods Mol Biol; 2023; 2666():279-297. PubMed ID: 37166672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
